1)Castro BM, de Abreu de Melo Y, Fernanda Dos Santos N, et al:Multi-agent simulation model for the evaluation of COVID-19 transmission. Comput Biol Med 136:104645,2021
2)Rashed EA, Hirata A:One-Year Lesson: Machine Learning Prediction of COVID-19 Positive Cases with Meteorological Data and Mobility Estimate in Japan. Int J Environ Res Public Health 18:5736,2021
3)Kodera S, Hikita K, Rashed EA, et al:The Effects of Time Window-Averaged Mobility on Effective Reproduction Number of COVID-19 Viral Variants in Urban Cities. J Urban Health 100:29-39,2023
4)国立感染症研究所:新型コロナウイルス ゲノムサーベイランスによる系統別検出状況(国立感染症研究所)(https://www.mhlw.go.jp/stf/seisakunitsuite/newpage_00061.html)(最終アクセス:2024年7月3日)
5)IHME COVID-19 Forecasting Team:Modeling COVID-19 scenarios for the United States. Nat Med 27:94-105,2021
6)Kodera S, Rashed EA, Hirata A:Estimation of Real-World Vaccination Effectiveness of mRNA COVID-19 Vaccines against Delta and Omicron Variants in Japan. Vaccines (Basel) 10:430,2022
7)Tartof SY, Slezak JM, Fischer H, et al:Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 398:1407-1416,2021
8)Andrews N, Stowe J, Kirsebom F, et al:Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med 386:1532-1546,2022
9)倉橋節也,横幕春樹,矢嶋耕平,他:地域への新型コロナウイルス感染者流入リスクとワクチン効果の影響評価.人工知能学会論文誌 37:C-L42_1-9,2022
10)Arashiro T, Arima Y, Muraoka H, et al:Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study). Clin Infect Dis 76:e108-e115,2023
11)Kodera S, Ueta H, Unemi T, et al:Population-Level Immunity for Transient Suppression of COVID-19 Waves in Japan from April 2021 to September 2022. Vaccines (Basel) 11:1457,2023
12)Sanada T, Honda T, Yasui F, et al:Serologic Survey of IgG Against SARS-CoV-2 Among Hospital Visitors Without a History of SARS-CoV-2 Infection in Tokyo, 2020-2021. J Epidemiol 32:105-111,2022